Onconetix, Inc. (ONCO)
1.02
+0.28
(+38.02%)
USD |
NASDAQ |
Sep 04, 16:00
0.813
-0.21
(-20.29%)
After-Hours: 20:00
Onconetix Research and Development Expense (Quarterly) : 0.0034M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0034M |
| March 31, 2026 | 0.0508M |
| December 31, 2025 | 0.0243M |
| September 30, 2025 | -0.0032M |
| June 30, 2025 | -0.1117M |
| March 31, 2025 | 0.0245M |
| December 31, 2024 | |
| September 30, 2024 | 0.1094M |
| June 30, 2024 | -0.0037M |
| March 31, 2024 | 0.049M |
| December 31, 2023 | |
| September 30, 2023 | 0.2192M |
| Date | Value |
|---|---|
| June 30, 2023 | 0.8469M |
| March 31, 2023 | 1.082M |
| December 31, 2022 | 1.206M |
| September 30, 2022 | 1.176M |
| June 30, 2022 | 1.294M |
| March 31, 2022 | 0.4551M |
| December 31, 2021 | 0.4373M |
| September 30, 2021 | 0.2699M |
| March 31, 2021 | 0.0882M |
| December 31, 2020 | 0.1017M |
| September 30, 2020 | 0.1029M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| BridgeBio Pharma, Inc. | 149.45M |
| Aprea Therapeutics, Inc. | 2.462M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |
| Anika Therapeutics, Inc. | 7.341M |